CD86 and neoplasm: As reported by Chen et al., the presence of CD86+ TAMs were significantly correlated with aggressive tumor phenotypes and it has been considered as a promising hepatocellular carcinoma prognostic biomarker, as a costimulatory molecule [28], CD86 is reported to be curative effect evaluation factor under chemotherapy treatment in colon cancer [29].